![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
New York, NY, April 23, 2024 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE American: VCXB) (“10X III”), announced today that New York Stock Exchange Regulation, Inc., by...
New York, NY, Jan. 31, 2024 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE American: VCXB, VCXB.U, VCXB WS) (“10X III”), announced today that NYSE Regulation (“NYSER”), by...
NEW YORK, NY (United States), Jan. 08, 2024 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (“10X III”) (NYSE American:VCXB), a publicly traded special purpose acquisition...
New York, NY, Nov. 28, 2023 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE American: VCXB) (“10X III”), announced today that New York Stock Exchange Regulation, Inc., by...
New York, NY, Oct. 04, 2023 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE: VCXB.U, VCXB, VCXB WS) (“10X III”) today announced that it is transferring the listing of its...
Addimmune’s investigational cell therapy, AGT103-T, makes gene modifications to the patients’ immune cells (T cells) that harden those cells against HIV infection and depletion, thus allowing...
Addimmune’s investigational cell therapy, AGT103-T, makes gene modifications to the patients’ immune cells (T cells) that harden those cells against HIV infection and depletion, thus allowing...
Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.27 | -2.35191637631 | 11.48 | 12.23 | 11.01 | 2135 | 11.17340241 | CS |
4 | -0.17 | -1.49384885764 | 11.38 | 12.23 | 10.86 | 1780 | 11.3555386 | CS |
12 | 0.01 | 0.0892857142857 | 11.2 | 12.23 | 9.82 | 1630 | 11.23510751 | CS |
26 | 0.48 | 4.4734389562 | 10.73 | 13 | 9.73 | 936 | 11.20537179 | CS |
52 | 0.6 | 5.65504241282 | 10.61 | 13 | 9.5 | 767 | 11.14812542 | CS |
156 | 0.6 | 5.65504241282 | 10.61 | 13 | 9.5 | 767 | 11.14812542 | CS |
260 | 0.6 | 5.65504241282 | 10.61 | 13 | 9.5 | 767 | 11.14812542 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions